Literature DB >> 16107232

New Antimicrobial Agents Active against Staphylococcus aureus.

James S Tan.   

Abstract

Entities:  

Year:  2005        PMID： 16107232     DOI： 10.1007/s11908-005-0009-x

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


× No keyword cloud information.
  8 in total

1.  Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects.

Authors:  J P Shaw; J Seroogy; K Kaniga; D L Higgins; M Kitt; S Barriere
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles.

Authors:  Loren G Miller; Francoise Perdreau-Remington; Gunter Rieg; Sheherbano Mehdi; Josh Perlroth; Arnold S Bayer; Angela W Tang; Tieu O Phung; Brad Spellberg
Journal:  N Engl J Med       Date:  2005-04-07       Impact factor: 91.245

3.  Methicillin-resistant Staphylococcus aureus disease in three communities.

Authors:  Scott K Fridkin; Jeffrey C Hageman; Melissa Morrison; Laurie Thomson Sanza; Kathryn Como-Sabetti; John A Jernigan; Kathleen Harriman; Lee H Harrison; Ruth Lynfield; Monica M Farley
Journal:  N Engl J Med       Date:  2005-04-07       Impact factor: 91.245

4.  Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.

Authors:  Martin E Stryjewski; William D O'Riordan; William K Lau; Francis D Pien; Lala M Dunbar; Marc Vallee; Vance G Fowler; Vivian H Chu; Elizabeth Spencer; Steven L Barriere; Michael M Kitt; Christopher H Cabell; G Ralph Corey
Journal:  Clin Infect Dis       Date:  2005-04-28       Impact factor: 9.079

5.  Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens.

Authors:  Issam Raad; Rabih Darouiche; Jose Vazquez; Arnold Lentnek; Ray Hachem; Hend Hanna; Beth Goldstein; Tim Henkel; Elyse Seltzer
Journal:  Clin Infect Dis       Date:  2005-01-07       Impact factor: 9.079

Review 6.  Tigecycline: clinical evidence and formulary positioning.

Authors:  Dilip Nathwani
Journal:  Int J Antimicrob Agents       Date:  2005-03       Impact factor: 5.283

7.  Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model.

Authors:  Li-Yan Yin; Luca Lazzarini; Fan Li; C Melinda Stevens; Jason H Calhoun
Journal:  J Antimicrob Chemother       Date:  2005-04-27       Impact factor: 5.790

Review 8.  Glycopeptide antibiotics: from conventional molecules to new derivatives.

Authors:  Françoise Van Bambeke; Yves Van Laethem; Patrice Courvalin; Paul M Tulkens
Journal:  Drugs       Date:  2004       Impact factor: 9.546
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.